ArticleCancers2022

Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study.

Andres Poveda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.